Development and exacerbation of pulmonary nontuberculous mycobacterial infection in patients with systemic autoimmune rheumatic diseases

References

• Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2010;6(11):644–52.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis. 2013;72(1):37–42.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):189–94.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011;21(4):343–51.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol. 2014;41(1):15–23.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab for in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod Rheumatol. 2014;24(3):390–8.
   PubMed Web of Science ®Google Scholar
• Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, et al. Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2016;26(4):491–8.
   PubMed Web of Science ®Google Scholar
• Ide S, Nakamura S, Yamamoto Y, Kohno Y, Fukuda Y, Ikeda H, et al. Epidemiology and clinical features of pulmonary nontuberculous mycobacteriosis in Nagasaki, Japan. PLoS One. 2015;10(5):e0128304.
   PubMed Web of Science ®Google Scholar
• Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, et al. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerg Infect Dis. 2016;22(6):1116–7.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Iwai K, Uchimura K, Okumura M, Yoshiyama T, Yoshimori K, et al. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Annals Ats. 2014;11(1):1–8.
   Google Scholar
• Tokuda H, Harigai M, Kameda H, Tomono K, Takayanagi N, Watanabe A, et al. Consensus statements for medical practice: biological agents and lung disease [Abridged English translation by the Japanese Respiratory Society]. Respir Investig. 2017;55(3):229–51.
   PubMed Web of Science ®Google Scholar
• Prevots DR, Marras TK. Epidemiology of human pulmonary infection with non-tuberculous mycobacteria: a review. Clin Chest Med. 2015;36(1):13–34.
   PubMed Web of Science ®Google Scholar
• Mok MY, Wong SSY, Chan TM, Fong DYT, Wong WS, Lau CS. Non-tuberculous mycobacterial infection in patients with systemic lupus erythematosus. Rheumatology. 2006;46(2):280–4.
   PubMed Web of Science ®Google Scholar
• Yamakawa H, Takayanagi N, Miyahara Y, Ishiguro T, Kanauchi T, Hoshi T, et al. Prognostic factors and radiographic outcomes of nontuberculous mycobacterial lung disease in rheumatoid arthritis. J Rheumatol. 2013;40(8):1307–15.
   PubMed Web of Science ®Google Scholar
• Yoo JW, Jo KW, Kang BH, Kim MY, Yoo B, Lee CK, et al. Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy. Eur Respir J. 2014;44(5):1289–95.
   PubMed Web of Science ®Google Scholar
• Liao TL, Lin CH, Shen GH, Chang CL, Lin CF, Chen DY. Risk for mycobacterial disease among patients with rheumatoid arthritis, Taiwan, 2001-2011. Emerg Infect Dis. 2015;21(8):1387–95.
   PubMed Web of Science ®Google Scholar
• Liao TL, Lin CF, Chen YM, Liu HJ, Chen DY. Risk factors and outcomes of nontuberculous mycobacterial disease among rheumatoid arthritis patients: a case-control study in a TB endemic area. Sci Rep. 2016;6:29443.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012;185(5):575–83.
   PubMed Web of Science ®Google Scholar
• Nontuberculous Mycobacteriosis Control Committee of the Japanese Society for Tuberculosis; Scientific Assembly for Infection and Tuberculosis of the Japanese Respiratory Society. Guidelines for chemotherapy of pulmonary nontuberculous mycobacterial disease – 2008. Kekkaku. 2011;86:37–9.
   PubMedGoogle Scholar
• Mori S, Tokuda H, Sakai F, Johkoh T, Mimori A, Nishimoto N, et al. Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a retrospective multicenter study in Japan. Mod Rheumatol. 2012;22(5):727–37.
   PubMed Web of Science ®Google Scholar
• Moore EH. Atypical mycobacterial infection in the lung: CT appearance. Radiology. 1993;187(3):777–82.
   PubMed Web of Science ®Google Scholar
• Cohen M, Sahn SA. Bronchiectasis in systemic diseases. Chest. 1999;116(4):1063–74.
   PubMed Web of Science ®Google Scholar
• Cowman SA, Jacob J, Obaidee S, Floto A, Wilson R, Haworth CS, et al. Latent class analysis to define radiological subgroups in pulmonary nontuberculous mycobacterial disease. BMC Pulm Med. 2018;18:145.
   PubMed Web of Science ®Google Scholar
• Hirose W, Harigai M, Uchiyama T, Itoh K, Ishizuka T, Matsumoto M, et al. Low body mass index and lymphocytopenia associate with Mycobacterium avium complex pulmonary disease in patients with rheumatoid arthritis. Mod Rheumatol. 2019;29(1):105–12.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yoon SH, Choi SM, Lee J, Lee C-H, Han SK, et al. Characteristics associated with progression in patients with of nontuberculous mycobacterial lung disease: a prospective cohort study. BMC Pulm Med. 2017;17:5.
   PubMed Web of Science ®Google Scholar
• Shaykhiev R, Crystal RG. Innate immunity and chronic obstructive pulmonary disease – a mini-review. Gerontology. 2013;59(6):481–9.
   PubMed Web of Science ®Google Scholar
• Hammad H, Lambrecht BN. Barrier epithelial cells and the control of type 2 immunity. Immunity. 2015;43(1):29–40.
   PubMed Web of Science ®Google Scholar
• Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174(8):928–34.
   PubMed Web of Science ®Google Scholar